CSIMarket
 


Acura Pharmaceuticals inc  (ACUR)
Other Ticker:  
 

Cumulative Acura Pharmaceuticals Inc's Working Capital Ratio for Trailing Twelve Months Period

ACUR's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ACUR Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
Y / Y Current Liabilities Growth -93.15 % -17.3 % -84.95 % 5.13 % 783.9 %
Y / Y Current Assets Growth -68.45 % -47.94 % -32.53 % -0.65 % 0.08 %
Working Capital Ratio for Trailing Twelve Months Period 0.38 0.27 0.31 0.26 0.26
Total Ranking # 5444 # 4697 # 4618 # 4883 # 4642
Seq. Current Liabilities Growth -47.45 % -11.71 % -85.55 % 2.15 % 534.77 %
Seq. Current Assets Growth -55.98 % -35.45 % -5.08 % 16.96 % -27.36 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2021
On the trailing twelve months basis Current Liabilities decreased faster than Acura Pharmaceuticals Inc's average Current Assets, this led to increase in in Acura Pharmaceuticals Inc's Working Capital Ratio for Trailing Twelve Months Period to 0.38, Working Capital Ratio for Trailing Twelve Months Period remained below Acura Pharmaceuticals inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 566 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Acura Pharmaceuticals Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ACUR
Working Capital Ratio ACUR in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 567
Sector # 1138
S&P 500 # 4924


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
3.89 1.13 0.14
(Sep. 30, 2015)   (Mar 31 2019)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Redhill Biopharma Ltd   1.02 
Cytodyn inc   0.94 
One World Products Inc   0.93 
Assertio Holdings inc   0.91 
Mallinckrodt Plc  0.89 
Sunwin Stevia International Inc.  0.88 
Abbvie inc   0.87 
The Greater Cannabis Company Inc   0.85 
Nexien Biopharma Inc   0.81 
First Wave Biopharma Inc   0.77 
Aridis Pharmaceuticals Inc   0.69 
Evofem Biosciences Inc   0.68 
International Stem Cell Corporation  0.68 
Moonlake Immunotherapeutics  0.60 
Conduit Pharmaceuticals Inc   0.59 
China Pharma Holdings Inc   0.54 
Takeda Pharmaceutical Company Limited  0.53 
Bespoke Extracts Inc   0.53 
American Bio Medica Corporation  0.47 
Janone Inc   0.46 
Emmaus Life Sciences Inc   0.45 
180 Life Sciences Corp  0.38 
Rapid Therapeutic Science Laboratories Inc   0.37 
Axim Biotechnologies Inc   0.36 
Nascent Biotech Inc  0.34 
Agex Therapeutics Inc   0.33 
Musclepharm Corporation  0.31 
Theralink Technologies Inc   0.30 
Acura Pharmaceuticals inc  0.23 
Viveon Health Acquisition Corp   0.22 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com